Zetia Name Accepted Based On Sponsor Data, Despite DMETS Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck/Schering-Plough’s market analysis of the Zetia tradename was sufficient to alleviate FDA’s concerns about name confusion, NDA review documents indicate.